JP2017000143A5 - - Google Patents

Download PDF

Info

Publication number
JP2017000143A5
JP2017000143A5 JP2016130526A JP2016130526A JP2017000143A5 JP 2017000143 A5 JP2017000143 A5 JP 2017000143A5 JP 2016130526 A JP2016130526 A JP 2016130526A JP 2016130526 A JP2016130526 A JP 2016130526A JP 2017000143 A5 JP2017000143 A5 JP 2017000143A5
Authority
JP
Japan
Prior art keywords
growth factor
fusion protein
tissue
cell
activation domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016130526A
Other languages
English (en)
Japanese (ja)
Other versions
JP6174763B2 (ja
JP2017000143A (ja
Filing date
Publication date
Priority claimed from US13/112,907 external-priority patent/US8691771B2/en
Application filed filed Critical
Publication of JP2017000143A publication Critical patent/JP2017000143A/ja
Publication of JP2017000143A5 publication Critical patent/JP2017000143A5/ja
Application granted granted Critical
Publication of JP6174763B2 publication Critical patent/JP6174763B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016130526A 2010-05-21 2016-06-30 二重特異的融合タンパク質 Active JP6174763B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34704010P 2010-05-21 2010-05-21
US61/347,040 2010-05-21
US13/112,907 US8691771B2 (en) 2010-05-21 2011-05-20 Bi-specific fusion proteins for tissue repair
US13/068,808 2011-05-20
US13/068,808 US9238080B2 (en) 2010-05-21 2011-05-20 Bi-specific fusion proteins
US13/112,907 2011-05-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013511403A Division JP6200806B2 (ja) 2010-05-21 2011-05-20 二重特異的融合タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017132859A Division JP6822911B2 (ja) 2010-05-21 2017-07-06 二重特異的融合タンパク質

Publications (3)

Publication Number Publication Date
JP2017000143A JP2017000143A (ja) 2017-01-05
JP2017000143A5 true JP2017000143A5 (enExample) 2017-06-22
JP6174763B2 JP6174763B2 (ja) 2017-08-02

Family

ID=44972647

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013511403A Active JP6200806B2 (ja) 2010-05-21 2011-05-20 二重特異的融合タンパク質
JP2016130526A Active JP6174763B2 (ja) 2010-05-21 2016-06-30 二重特異的融合タンパク質
JP2017132859A Active JP6822911B2 (ja) 2010-05-21 2017-07-06 二重特異的融合タンパク質
JP2019117073A Active JP6965311B2 (ja) 2010-05-21 2019-06-25 二重特異的融合タンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013511403A Active JP6200806B2 (ja) 2010-05-21 2011-05-20 二重特異的融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017132859A Active JP6822911B2 (ja) 2010-05-21 2017-07-06 二重特異的融合タンパク質
JP2019117073A Active JP6965311B2 (ja) 2010-05-21 2019-06-25 二重特異的融合タンパク質

Country Status (9)

Country Link
US (11) US9238080B2 (enExample)
EP (1) EP2571992B1 (enExample)
JP (4) JP6200806B2 (enExample)
CN (1) CN103124788B (enExample)
AU (1) AU2011255238B2 (enExample)
BR (1) BR112012029611A2 (enExample)
CA (1) CA2800173C (enExample)
ES (1) ES2674567T3 (enExample)
WO (1) WO2011146902A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
ES2630253T3 (es) 2009-02-11 2017-08-18 Albumedix A/S Variantes de albúmina y conjugados
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
CN102939304B (zh) 2010-04-09 2017-04-19 阿尔布麦狄克斯公司 白蛋白衍生物和变体
CN103124788B (zh) * 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CA2834516A1 (en) * 2011-04-28 2012-11-01 The Feinstein Institute For Medical Research Mfg-e8 and uses thereof
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
JP6441682B2 (ja) 2012-03-16 2018-12-19 アルブミディクス リミティド アルブミン変種
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
EP2864360B1 (en) 2012-06-25 2017-09-06 The Brigham and Women's Hospital, Inc. Targeted therapeutics
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
JP6487328B2 (ja) 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
WO2014139468A1 (en) * 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
CN113501880A (zh) 2014-05-02 2021-10-15 动量制药公司 涉及工程化Fc构建体的组合物和方法
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP2018513155A (ja) 2015-04-17 2018-05-24 メリマック ファーマシューティカルズ インコーポレーティッド セリバンツマブを用いた併用療法
CN104946656B (zh) * 2015-06-08 2018-08-17 吉林省农业科学院 一种人源碱性成纤维细胞生长因子、烟草叶绿体表达载体及生产方法
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
MX2018001825A (es) 2015-08-20 2018-05-07 Albumedix As Variantes y conjugados de albumina.
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
CN108367048B (zh) * 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
US20190002516A1 (en) * 2015-12-21 2019-01-03 Hefei Lifeon Pharmaceutical Co., Ltd. Drug Design Method, Obtained Drug and Application Thereof
US20190365656A1 (en) * 2016-01-04 2019-12-05 Cour Pharmaceuticals Development Company, Inc. Particles encapsulating fusion proteins containing linked epitopes
US10301391B2 (en) 2016-02-03 2019-05-28 Amgen Research (Munich) Gmbh BCMA and CD3 bispecific T cell engaging antibody constructs
PL3411404T3 (pl) 2016-02-03 2023-02-13 Amgen Research (Munich) Gmbh Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US20190091227A1 (en) 2016-03-15 2019-03-28 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
AU2017272111B2 (en) 2016-05-23 2024-05-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
SG10202107391YA (en) 2017-01-06 2021-08-30 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
GB2580228B (en) * 2017-07-03 2022-11-02 Torque Therapeutics Inc Immunostimulatory fusion molecules and uses thereof
US11352404B2 (en) * 2017-07-24 2022-06-07 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use
CN113214410A (zh) * 2017-11-04 2021-08-06 海南大学 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法
US11464803B2 (en) * 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
GB201919019D0 (en) * 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
US20230151109A1 (en) * 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9
EP4103609A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
WO2022026902A2 (en) 2020-07-30 2022-02-03 Silver Creek Pharmaceuticals, Inc. Chimeric proteins and methods of use for treatment of central nervous system disorders
CN112266417B (zh) * 2020-10-27 2022-02-11 温州医科大学 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
WO2022092974A1 (ko) * 2020-10-30 2022-05-05 (주)셀레메디 항체 유사 단백질 및 그 용도
US11946055B2 (en) * 2020-12-10 2024-04-02 The Regents Of The University Of California Protein engineering via error-prone orthogonal replication and yeast surface display
US20240218030A1 (en) * 2021-05-03 2024-07-04 Cellemedy Co., Ltd Mutated ferritin protein
CN117659178B (zh) * 2022-08-23 2024-09-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体或其功能性片段、检测甲型流感病毒的试剂和试剂盒
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
CN118420712A (zh) * 2023-02-01 2024-08-02 上海健信生物医药科技有限公司 一种三特异性抗体技术平台及其应用
CN116983407B (zh) * 2023-08-03 2025-10-28 艾可泰科(浙江)控股有限公司 一种治疗膝关节炎的新一代干细胞治疗剂及其制备工艺
CN117736344B (zh) * 2024-01-30 2024-06-21 南通大学 具有自组装性能的重复结构单元重组蛋白ⅡAⅡB-ⅡAⅡBrQTY及应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819826D0 (en) 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5679771A (en) 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
DK0574395T3 (da) * 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
WO1994028133A1 (en) * 1993-05-21 1994-12-08 Amgen Inc. Recombinant neu differentiation factors
CA2190752A1 (en) 1994-05-24 1995-11-30 George N. Cox Modified insulin-like growth factors
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
WO1997039032A1 (en) 1996-04-17 1997-10-23 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
NZ508873A (en) * 1998-07-13 2003-10-31 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6387663B1 (en) * 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
AU762047B2 (en) 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE316980T1 (de) 1999-07-21 2006-02-15 Univ Southern California Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
CA2419561A1 (en) 2000-08-29 2002-03-07 Colorado State University Research Foundation Method for treating the central nervous system by administration of igf structural analogs
EP1399483B1 (en) * 2001-01-05 2010-04-14 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7049286B2 (en) * 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
AU2008200706B2 (en) 2001-10-16 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
AU2003241313A1 (en) 2002-04-23 2003-11-10 Roger Williams Hospital Compositions and methods for stem cell delivery
CN1659180B (zh) 2002-06-06 2010-06-02 温子坚 新型的重组抗凝血蛋白
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040213738A1 (en) 2003-03-31 2004-10-28 Susan Croll-Kalish CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
WO2004100961A1 (ja) 2003-05-19 2004-11-25 Seikagaku Corporation 硫酸基転移酵素阻害剤
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
JP2007517506A (ja) * 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
DK1729795T3 (en) * 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin fusion proteins
CA2565827A1 (en) 2004-05-05 2005-12-15 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060018897A1 (en) 2004-06-28 2006-01-26 Transtarget Inc. Bispecific antibodies
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
JP2008510732A (ja) 2004-08-20 2008-04-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 心臓組織の損傷を処置、予防、阻害、または緩和する方法
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
JP2008517917A (ja) 2004-10-21 2008-05-29 アイジーエフ オンコロジー エルエルシー 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド
KR101236450B1 (ko) * 2004-12-21 2013-02-25 무스크 파운데이션 포 리서치 디벨롭먼트 상처 치유 및 조직 재생을 촉진하기 위한 조성물 및 방법
WO2006074390A2 (en) 2005-01-07 2006-07-13 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
AU2006204913A1 (en) 2005-01-14 2006-07-20 Cytogen Corporation Combination cancer therapy with anti-PSMA antibodies
US8956616B2 (en) * 2005-01-24 2015-02-17 Board Of Regents, The University Of Texas System Constructs binding to phosphatidylserine and their use in disease treatment
US20090246206A1 (en) 2005-02-23 2009-10-01 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
WO2006128125A2 (en) 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
ES2617002T3 (es) 2005-12-12 2017-06-15 Mosamedix B.V. Derivados de anexina adecuados para la prefocalización en terapia y diagnóstico
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
KR20080098504A (ko) * 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
EP1986684A2 (en) 2006-02-15 2008-11-05 ImClone Systems Incorporated Functional antibodies
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
SE530073C2 (sv) 2007-01-23 2008-02-26 Teknikbolaget K Samuelsson Ab Sprutmunstycksanordning för brandsläckningssystem
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
US8889140B2 (en) 2007-05-31 2014-11-18 Transtarget, Inc. Compositions and methods for tissue repair
EP2173890B1 (en) 2007-06-21 2011-03-16 Technische Universität München Biological active proteins having increased in vivo and/or vitro stability
WO2009030720A2 (en) 2007-09-06 2009-03-12 Novozymes Biopharma Dk A/S Process for producing a recombinant protein
WO2009126920A2 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010087976A2 (en) 2009-01-31 2010-08-05 Igf Oncology, Llc Anti-cancer protein-platinum conjugates
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
WO2011011072A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59
AU2010306774A1 (en) 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
CN103124788B (zh) * 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
JP5875597B2 (ja) 2010-12-08 2016-03-02 ヴィアサイト，インコーポレイテッド ヒト万能性幹細胞の成長を阻害する薬剤および方法
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
CN109180802A (zh) 2011-12-15 2019-01-11 爱德迪安（北京）生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
MX2015013803A (es) 2013-03-29 2016-02-16 Merrimack Pharmaceuticals Inc Proteina de fusion de enlace al cartilago.
WO2015106224A2 (en) 2014-01-12 2015-07-16 Hugh Mctavish Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
CN108367048B (zh) * 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3857888A4 (en) 2018-10-06 2022-08-03 HFI Innovation Inc. METHOD AND APPARATUS FOR AN AREA OF A SHARED MERGER CANDIDATE LIST FOR ENABLING VIDEO CODING

Similar Documents

Publication Publication Date Title
JP2017000143A5 (enExample)
JP2013530146A5 (enExample)
JP2019196365A5 (enExample)
Ren et al. Osteogenesis on nanoparticulate mineralized collagen scaffolds via autogenous activation of the canonical BMP receptor signaling pathway
PH12017501792B1 (en) Recombinant binding proteins and their use
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
MY204384A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
Kaneko et al. A 3D nanofibrous hydrogel and collagen sponge scaffold promotes locomotor functional recovery, spinal repair, and neuronal regeneration after complete transection of the spinal cord in adult rats
EA200802289A1 (ru) Направляемые к мишени антителами цитокины для терапии
MY159837A (en) Therapeutic dll4 binding proteins
WO2013184960A3 (en) Chimeric fibroblast growth factor 23 proteins and methods of use
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
Sufen et al. bFGF and PDGF‐BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells
EP3321276A3 (en) Fusion proteins for treating metabolic disorders
MX2017013520A (es) Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular.
NO20083793L (no) Antistoffer mot amyloid-beta peptid
JP2016521688A5 (enExample)
TN2019000119A1 (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
WO2018081726A3 (en) Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
AR073078A1 (es) Construcciones flt (vegf- factor de crecimiento del endotelio vascular) solubles para el tratamiento del cancer.
WO2019014360A8 (en) POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF
Lowery et al. A survey of strategies to modulate the bone morphogenetic protein signaling pathway: current and future perspectives
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use